Methicillin-resistant Staphylococcus aureus: the superbug

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 4, 2010, Pages

  Ippolito, Giuseppe ^a   Leone, Sebastiano ^b   Lauria, Francesco N ^a   Nicastri, Emanuele ^a   Wenzel, Richard P ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CEFTOBIPROLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; HAMAMELITANNIN; ICLAPRIM; LINEZOLID; ORITAVANCIN; POLYSACCHARIDE; QUORUM SENSING INHIBITOR; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CREATINE KINASE BLOOD LEVEL; DEVICE INFECTION; DRUG WITHDRAWAL; HEMODIALYSIS PATIENT; HOSPITAL COST; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; QUORUM SENSING; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VACCINATION; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 78149280829     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.05.003     Document Type: Article

References (60)

1. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
2. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-885.
3. Jevons M.P. 'Celbenin'-resistant staphylococci. BMJ 1961, i::124-125.
4. Ayliffe G.A. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997, 24(Suppl 1):74-79.
5. Casey A.L., Lambert P.A., Elliott T.S. Staphylococci. Int J Antimicrob Agents 2007, 29(Suppl 3):23-32.
6. Fridkin S.K., Hill H.A., Volkova N.V., Edwards J.R., Lawton R.M., Gaynes R.P., et al. Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002, 8:697-701.
7. Tiemersma E.W., Bronzwaer S.L., Lyytikäinen O., Degener J.E., Schrijnemakers P., Bruinsma N., et al. European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004, 10:1627-1634.
8. Turnidge J.D., Bell J.M. Methicillin-resistant Staphylococcus aureus evolution in Australia over 35 years. Microb Drug Resist 2000, 6:223-229.
9. Furuno J.P., Hebden J.N., Standiford H.C., Perencevich E.N., Miller R.R., Moore A.C., et al. Prevalence of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii in a long-term acute care facility. Am J Infect Control 2008, 36:468-471.
10. Manzur A., Gavalda L., Ruiz de Gopegui E., Mariscal D., Dominguez M.A., Perez J.L., et al. Prevalence of methicillin-resistant Staphylococcus aureus and factors associated with colonization among residents in community long-term-care facilities in Spain. Clin Microbiol Infect 2008, 14:867-872.
11. Carleton H.A., Diep B.A., Charlebois E.D., Sensabaugh G.F., Perdreau-Remington F. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis 2004, 190:1730-1738.
12. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005, 40:562-573.
13. Chambers H.F. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005, 352:1485-1487.
14. Maltezou H.C., Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2006, 27:87-96.
15. Hota B., Ellenbogen C., Hayden M.K., Aroutcheva A., Rice T.W., Weinstein R.A. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission?. Arch Intern Med 2007, 167:1026-1033.
16. van Belkum A., Melles D.C., Peeters J.K., van Leeuwen W.B., van Duijkeren E., Huijsdens X.W., et al. Methicillin-resistant and -susceptible Staphylococcus aureus sequence type 398 in pigs and humans. Emerg Infect Dis 2008, 14:479-483.
17. Morgan M. Methicillin-resistant Staphylococcus aureus and animals: zoonosis or humanosis?. J Antimicrob Chemother 2008, 62:1181-1187.
18. Sing A., Tuschak C., Hörmansdorfer S. Methicillin-resistant Staphylococcus aureus in a family and its pet cat. N Engl J Med 2008, 358:1200-1201.
19. Engemann J.J., Carmeli Y., Cosgrove S.E., Fowler V.G., Bronstein M.Z., Trivette S.L., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36:592-598.
20. Kopp B.J., Nix D.E., Armstrong E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004, 38:1377-1382.
21. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
22. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
23. Whitby M., McLaws M.L., Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001, 175:264-267.
24. Melzer M., Eykyn S.J., Gransden W.R., Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003, 37:1453-1460.
25. Zahar J.R., Clec'h C., Tafflet M., Garrouste-Orgeas M., Jamali S., Mourvillier B., et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?. Clin Infect Dis 2005, 41:1224-1231.
26. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000, 31(Suppl 4):131-138.
27. Kaye K.S., Anderson D.J., Choi Y., Link K., Thacker P., Sexton D.J. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis 2008, 46:1568-1577.
28. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005, 11(Suppl 3):29-35.
29. Louie R.F., Tang Z., Albertson T.E., Cohen S., Tran N.K., Kost G.J. Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia. Crit Care Med 2008, 36:1487-1492.
30. Peters R.P., van Agtmael M.A., Gierveld S., Danner S.A., Groeneveld A.B., Vandenbroucke-Grauls C.M., et al. Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in the intensive care unit. J Clin Microbiol 2007, 45:3641-3646.
31. Huang S.S., Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003, 36:281-285.
32. Datta R., Huang S.S. Risk of infection and death due to methicillin-resistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 2008, 47:176-181.
33. Robicsek A., Beaumont J.L., Peterson L.R. Duration of colonization with methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2009, 48:910-913.
34. Robicsek A., Beaumont J.L., Paule S.M., Hacek D.M., Thomson R.B., Kaul K.L., et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008, 148:409-418.
35. Harbarth S., Fankhauser C., Schrenzel J., Christenson J., Gervaz P., Bandiera-Clerc C., et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008, 299:1149-1157.
36. Karchmer A.W., Bayer A.S. Methicillin-resistant Staphylococcus aureus: an evolving clinical challenge. Clin Infect Dis 2008, 46(Suppl 5):342-343.
37. Gould I.M. The problem with glycopeptides. Int J Antimicrob Agents 2007, 30:1-3.
38. Wang G., Hindler J.F., Ward K.W., Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
39. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
40. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
41. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
42. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
43. Garau J., Bouza E., Chastre J., Gudiol F., Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009, 15:125-136.
44. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
45. Drew R.H. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007, 27:227-249.
46. Bozdogan B., Appelbaum P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004, 23:113-119.
47. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005, 25:185-192.
48. Carpenter C.F., Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
49. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
50. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:1079-1082.
51. Moise P.A., North D., Steenbergen J.N., Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009, 9:617-624.
52. Enoch D.A., Bygott J.M., Daly M.L., Karas J.A. Daptomycin. J Infect 2007, 55:205-213.
53. Lentino J.R., Narita M., Yu V.L. New antimicrobial agents as therapy for resistant Gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008, 27:3-15.
54. Cornaglia G., Rossolini G.M. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:218-223.
55. Lynch S.V., Wiener-Kronish J.P. Novel strategies to combat bacterial virulence. Curr Opin Crit Care 2008, 14:593-599.
56. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346:491-496.
57. Bloom B., Schelonka R., Kueser T., Walker W., Jung E., Kaufman D., et al. INH-A21 Phase II Study Team. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005, 24:858-866.
58. Schaffer A.C., Lee J.C. Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 2008, 32(Suppl 1):71-78.
59. Rasmussen T.B., Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol 2006, 296:149-161.
60. Kiran M.D., Adikesavan N.V., Cirioni O., Giacometti A., Silvestri C., Scalise G., et al. Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening. Mol Pharmacol 2008, 73:1578-1586.